Market Place
Sourcing Support
TriSalus Partners with Geo-Med to Expand TriNav Access for Veterans
11 Nov 2024 //
BUSINESSWIRE
TriSalus Launches TriNav® LV Infusion System & TriGuide™ Catheters
07 Nov 2024 //
BUSINESSWIRE
TriSalus Life to Participate in 2024 Maxim Healthcare Virtual Summit
14 Oct 2024 //
BUSINESSWIRE
TriSalus Appoints Riad Salem To Advisory Board
26 Sep 2024 //
BUSINESSWIRE
TriSalus Reports PEDD Improves Tumor Therapeutic Delivery
23 Sep 2024 //
BUSINESSWIRE
TriSalus Reports Q2 2024 Financial Results and Business Update
15 Aug 2024 //
BUSINESSWIRE
TriSalus Life Sciences To Host Q2 2024 Results Call
01 Aug 2024 //
BUSINESSWIRE
TriSalus Life Sciences Announces Results Of Exchange Offer
26 Jun 2024 //
BUSINESSWIRE
TriSalus` PERIO-02 Nelitolimod Delivery Data In HCC, Cholangiocarcinoma
03 Jun 2024 //
BUSINESSWIRE
Trisalus Warrant Exchange Offer: Consent Solicitation Commencement Announced
24 May 2024 //
BUSINESSWIRE
TriSalus Reports Q1 2024 Financial Results and Business Update
15 May 2024 //
BUSINESSWIRE
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
07 May 2024 //
BUSINESSWIRE
TriSalus to Host First Quarter 2024 Financial Results Conference Call
06 May 2024 //
BUSINESSWIRE
TriSalus $50M Debt Financing from OrbiMed for TriNav® Growth
30 Apr 2024 //
BUSINESSWIRE
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
01 Apr 2024 //
BUSINESSWIRE
TriSalus Presentations at the Society of Interventional Radiology Meeting
26 Mar 2024 //
BUSINESSWIRE
TriSalus Announces Presentations at the Upcoming 2024 SIR Annual Meeting
21 Mar 2024 //
BUSINESSWIRE
TriSalus Life Announces Real-World Data Demonstrating the Ability of TriNav
29 Feb 2024 //
BUSINESSWIRE
TriSalus Life Announces CMS Reimbursement for the TriNav® Infusion System
14 Dec 2023 //
BUSINESSWIRE
TriSalus Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
TriSalus Life to Host Third Quarter 2023 Financial Results Conference Call
07 Nov 2023 //
BUSINESSWIRE
Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC
04 Nov 2023 //
BUSINESSWIRE
TriSalus Life Presents Data for SD-101 Delivered by TriSalus Infusion System
03 Nov 2023 //
BUSINESSWIRE
TriSalus Life Announces Additional Data Presentations on Liver Metastases
25 Oct 2023 //
BUSINESSWIRE
TriSalus Life Appoints Jodi Devlin as President of TriSalus Therapeutics
06 Sep 2023 //
BUSINESSWIRE
TriSalus Life Sciences Presents New Data at AACR for SD-101
20 Apr 2023 //
BUSINESSWIRE
TriSalus Highlights Pressure-Enabled Regional Immuno-Oncology Trial Progress
15 Dec 2022 //
BUSINESSWIRE
TriSalus Provides Updates on PERIO 01 and 02 Clinical Studies
21 Nov 2022 //
BUSINESSWIRE
TriSalus inks SPAC merger to fund infusion tech cancer trials
16 Nov 2022 //
FIERCEPHARMA
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech
14 Nov 2022 //
BIOSPACE
TriSalus enrols first subject in study of liver cancer treatment
11 May 2022 //
CLINICALTRIALSARENA
TriSalus Life Sciences Enrolls First Patient in PERIO-02 Trial of SD-101
10 May 2022 //
BUSINESSWIRE
TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisors
10 Feb 2022 //
BUSINESSWIRE
TriSalus Collaborates with University of Colorado for Immuno-oncology Treatments
20 Jan 2022 //
BUSINESSWIRE
TriSalus Life Sciences Announces 1st Patient Enrolled in PERIO-01 Clinical Trial
07 Sep 2021 //
BUSINESSWIRE
TriSalus Life Sciences Presents Data at American Association of Cancer Research
14 Apr 2021 //
BUSINESSWIRE
TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration
08 Apr 2021 //
BUSINESSWIRE
TriSalus Announces Therapeutic Strategy after Acquisition of SD-101
24 Sep 2020 //
BUSINESSWIRE
TriSalus Life Sciences Acquires Dynavax`s SD-101 Oncology Program To $250M
03 Aug 2020 //
GLOBENEWSWIRE
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Agreement for to $250M
03 Aug 2020 //
GLOBENEWSWIRE
